Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tests on Day of Discharge Are Often Never Seen

By LabMedica International staff writers
Posted on 06 Sep 2012
The results of tests ordered on the day of a patient's discharge from the hospital made up a disproportionate number of tests that doctors never reviewed, according to a new study. More...


Researchers at the Australian Institute of Health Innovations (Sydney, Australia), and St Vincent's Hospital (Sydney, Australia) reviewed data on 662,858 clinical pathology tests ordered during 6,736 inpatient admissions at a single hospital. In all, more than one-third of admissions (37.7%) had at least one test that was not reviewed before discharge, and 28% had unreviewed results two months postdischarge. Of these, test results that were still pending--and thus, not yet available--at discharge accounted for only 28.6% of the tests that were not reviewed.

After analysis, the researchers found that although only a fraction of all tests were ordered on the day of discharge, those ordered on the last day of the hospital stay accounted for nearly half (46.8%) of tests that were not reviewed at discharge, and 41.1% of those that had not been looked at by two months. Of all of the unreviewed tests, 14.7% of those at discharge and 10.8% of those at two months later had abnormal test results. In all, about two-thirds of all unreviewed, abnormal results came from tests ordered on the day of discharge. The study was published online as a research letter on August 13, 2012, in Archives of Internal Medicine.

“When discharge dates are known, or the average length of stay for an admission is well defined, it would be possible to estimate the time available for review,” suggested lead author to Enrico Coiera, MBBS, PhD. “This information can be used to trigger computer alerts when tests are being ordered electronically. Alerts could advise clinicians either that it is unlikely those results will be posted before discharge, or that the tests simply have a high risk of being missed.”

Related Links:

Australian Institute of Health Innovations
St Vincent's Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.